Pfizer Inc. (PFE) Wins FDA Nod To Use Talzenna + Xtandi Earlier in HRR-Mutated mHSPC

What happened

The FDA approved Talzenna plus Xtandi for HRR gene-mutated metastatic hormone-sensitive prostate cancer, widening Pfizer's earlier approval in later-line disease. The decision followed Priority Review and was supported by the Phase 3 TALAPRO-3 trial.

Confirmed

Global impact / market context

Treating patients earlier in the disease can reach more people than a later-line label, which may lift Pfizer's revenue from these two drugs if testing finds the mutations. Wider mutation coverage including BRCA and non-BRCA HRR enlarges the possible patient group.

Analyst inference

This is a mid-cycle label expansion of a 2023 U.S. approval, so it adds to an existing franchise rather than launching a new product. Upside depends on how many patients get biomarker testing and on EMA review timing.

Analyst inference

What to watch

1. EMA review is underway, and approval outside the U.S. would add revenue if granted. Confirmed
2. Watch uptake of the combination in biomarker-tested metastatic hormone-sensitive prostate cancer, since adoption hinges on testing rates. Proposed
3. Publication of full TALAPRO-3 data, including overall survival which is a key secondary measure, could shape how doctors adopt the regimen. Analyst inference

Evidence

• Original source link unavailable